Tarsus Pharmaceuticals, Inc.
TARS evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $3.83B
- Lead Asset:
- TP-03 (Phase 4)
What it means
What to watch
Prepared research question
What matters most for TARS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TARS
Tarsus Pharmaceuticals, Inc. (TARS) is a publicly traded biopharmaceutical company focused on developing and commercializing lotilaner-based therapies for eye care, dermatology, and infectious disease prevention, with a recently completed acquisition of Alkeus Pharmaceuticals to expand its ophthalmology pipeline.
Key risk: Ongoing net losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.83B
Cash Runway
—
Lead Asset
TP-03 (Phase 4)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 58 clinical trials for Tarsus Pharmaceuticals, Inc..
Tarsus Pharmaceuticals, Inc. (TARS) is a publicly traded biopharmaceutical company focused on developing and commercializing lotilaner-based therapies for eye care, dermatology, and infectious disease prevention, with a recently completed acquisition of Alkeus Pharmaceuticals to expand its ophthalmology pipeline.
- Cash & equivalents of $204.6M, total revenue of $173.9M, net loss of -$18.6M, shareholders' equity of $346.7M, and total debt of $75.0M as of 2026-06-30 [sec].
- Commercial product XDEMVY (lotilaner ophthalmic solution) launched in August 2023 for Demodex blepharitis; additional regulatory approvals for TP-03 in China and Macau triggered a $15.0M milestone payment in March 2026 [sec_mda · as of 2026-08-06].
- Phase 2 trials ongoing: KORE Trial (TP-04 for ocular rosacea, topline expected H1 2027) and Calliope Trial (TP-05 for Lyme disease prophylaxis, topline expected H1 2027) [sec_mda · as of 2026-05-06].
- Completed acquisition of Alkeus Pharmaceuticals on September 4, 2026, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt's disease [news · published 2026-09-04].
- Net losses were $25.5M and $45.5M for the six months ended June 30, 2026 and 2025, respectively, with expectations of increased operating expenses [sec_mda · as of 2026-08-06].
What works
- Strong commercial momentum with XDEMVY launch and growing sales, plus a $15.0M milestone from TP-03 approval in China [sec_mda · as of 2026-08-06].
- Differentiated pipeline leveraging lotilaner's unique mechanism (GABA-Cl inhibition in parasites, no human target) for multiple high-unmet-need indications [sec · filed 2026-04-28].
- Recent acquisition of Alkeus adds a Phase 3 oral therapy for Stargardt's disease, expanding leadership in eye care [news · published 2026-09-04].
- Solid cash position of $204.6M as of 2026-06-30 provides runway for ongoing clinical programs and commercialization [sec].
What to weigh
- Net loss of -$18.6M for the six months ended 2026-06-30 and accumulated net losses of $25.5M in the same period, with operating expenses expected to increase [sec][sec_mda · as of 2026-08-06].
- Phase 3 trial for TP-05 (Lyme disease prophylaxis) would require a large field study with thousands of patients, and the company believes partnering may be the best path forward [sec_mda · as of 2026-05-06].
- Dependence on third-party collaborators for manufacturing, clinical trials, and commercialization in licensed territories introduces execution risk [sec_mda · as of 2026-08-06].
- Potential need for additional capital to fully develop pipeline and execute business strategy, with risk of unfavorable terms if funding is raised through collaborations or licensing [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Lotilaner's mechanism of action targets parasite-specific GABA-Cl channels with no human inhibition.
“lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride ("GABA-Cl") channels with no GABA-Cl inhibition in humans.”
SEC filings · April 28, 2026
Phase 2 KORE Trial for TP-04 initiated December 2025 with topline results expected first half of 2027.
“In December 2025, we initiated a Phase 2 clinical trial (the "KORE Trial") evaluating TP-04, a lotilaner-based sterile ophthalmic gel formulation for the potential treatment of ocular rosacea. The KORE Trial continues to progress, with topline results expected in the first half of 2027.”
SEC MD&A · May 6, 2026
Acquisition of Alkeus completed on September 4, 2026, adding gildeuretinol for Stargardt's disease.
“Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc.”
News · September 4, 2026
Net losses of $25.5M for six months ended June 30, 2026.
“25.5 million and $45.5 million for the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Ongoing net losses — Net loss of $18.6M for H1 2026 and accumulated net losses of $25.5M; expenses expected to rise [sec][sec_mda · as of 2026-08-06].
- TP-05 Phase 3 complexity — Phase 3 for Lyme disease requires large field study; company may need to partner to advance [sec_mda · as of 2026-05-06].
- Dependence on third parties — Relies on collaborators for manufacturing, trials, and commercialization; any disruption could delay programs [sec_mda · as of 2026-08-06].
- Potential capital needs — May require additional funding; could force unfavorable licensing terms or program delays [sec_mda · as of 2026-08-06].
What to watch
- Topline results from Phase 2 KORE Trial (TP-04 for ocular rosacea) expected H1 2027 [sec_mda · as of 2026-05-06].
- Topline results from Phase 2 Calliope Trial (TP-05 for Lyme disease prophylaxis) expected H1 2027 [sec_mda · as of 2026-05-06].
- Integration and progress of Alkeus' gildeuretinol (ALK-001) Phase 3 program for Stargardt's disease following acquisition completion [news · published 2026-09-04].
- Commercial performance of XDEMVY and potential additional regulatory approvals for TP-03 in Europe and Japan [sec_mda · as of 2026-08-06].
Sources: News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Tarsus Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tarsus Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.76 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 11.1%
- Days to cover
- 9.0
- Shares short
- 4,575,347
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TARS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. (TARS) is a publicly traded biopharmaceutical company focused on developing and commercializing lotilaner-based therapies for eye care, dermatology, and infectious disease prevention, with a recently completed acquisition of Alkeus Pharmaceuticals to expand its ophthalmology pipeline.
What is Tarsus Pharmaceuticals, Inc.'s lead drug candidate?
Tarsus Pharmaceuticals, Inc.'s most advanced tracked candidate is TP-03 (Phase 4) for Meibomian Gland Dysfunction.
Who is the CEO of Tarsus Pharmaceuticals, Inc.?
Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals, Inc. (TARS).
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. (TARS) is headquartered in Irvine, CA, United States.
What therapeutic areas does Tarsus Pharmaceuticals, Inc. focus on?
Tarsus Pharmaceuticals, Inc. develops therapies across Oncology, Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Respiratory, Pain, Dermatology, Nephrology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.